Diagnostic value of combined detection of autoantibodies against p53 and Bmi-1 in lung cancer
10.3760/cma.j.issn.1008-1372.2017.11.011
- VernacularTitle:p53自身抗体和Bmi-1自身抗体联合检测在肺癌诊断中的价值
- Author:
Lisheng HUANG
1
;
Yuhao LUO
;
Xuefen WENG
;
Yuhui PENG
;
Yiwei XU
Author Information
1. 汕头大学医学院附属肿瘤医院放疗科
- Keywords:
Repressor proteins/DU;
Nuclear proteins/DU;
Tumor suppressor protein p53/DU;
Autoantibodies/DU;
Lung neoplasms/DI
- From:
Journal of Chinese Physician
2017;19(11):1645-1648
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the diagnostic value of combined detection of serum autoantibodies against against p53 and Bmi-1 in lung cancer (LC).Methods Serum levels of autoantibodies against p53 and Bmi-1 were measured by enzyme-linked immunosorbent assay (ELISA) in 92 patients with LC and 80 normal controls.The combined diagnostic value was evaluated with the receiver operating characteristic (ROC) curve.Results The serum levels of autoantibodies against p53 and Bmi-1 were significantly higher in LC than in normal controls (0.438 ±0.705 vs 0.045 ±0.035,Z =-7.667,P ＜0.01;0.117±0.061 vs 0.068 ±0.031,Z =-7.179,P ＜0.01).The levels of autoantibodies against p53 and Bmi-1 were not related to age,gender,pathological classification,lymph node status or tumor-node-metastasis (TNM) stage (P ＞ 0.05).The combined detection of two autoantibodies provided an enhanced sensitivity of 63.0％,a specificity of 91.2％ and an area under curve (AUC) of 0.881,which showed better diagnostic efficiency compared to individual autoantibodies.Conclusions Combined detection of autoantibodies against p53 and Bmi-1 shows good diagnostic value,which may aid diagnosis of LC.
